Sionna licenses clinical-stage cystic fibrosis assets from AbbVie shortly after large Series C

Kyle LaHucik

Senior Reporter

Sionna Therapeutics snagged the exclusive worldwide license to three of AbbVie’s cystic fibrosis drug candidates as the biotech aims to beef up its work in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sionna licenses clinical-stage cystic fibrosis assets from AbbVie shortly after large Series C

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sion­na li­cens­es clin­i­cal-stage cys­tic fi­bro­sis as­sets from Ab­b­Vie short­ly af­ter large Se­ries C

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sionna licenses clinical-stage cystic fibrosis assets from AbbVie shortly after large Series C